ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 142 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.10 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $207,382 | -88.5% | 18,566 | -77.9% | 0.00% | – |
| Q2 2023 | $1,800,233 | -85.2% | 84,123 | -72.1% | 0.00% | -100.0% |
| Q1 2023 | $12,203,579 | +146.1% | 301,770 | +183.1% | 0.00% | +200.0% |
| Q4 2022 | $4,958,987 | -73.2% | 106,599 | -70.1% | 0.00% | -83.3% |
| Q3 2022 | $18,474,000 | -21.8% | 356,177 | -28.7% | 0.01% | -14.3% |
| Q2 2022 | $23,613,000 | -3.0% | 499,530 | +46.1% | 0.01% | +16.7% |
| Q1 2022 | $24,343,000 | +12.3% | 342,007 | +18.0% | 0.01% | +20.0% |
| Q4 2021 | $21,674,000 | +259.3% | 289,844 | +173.0% | 0.01% | +150.0% |
| Q3 2021 | $6,032,000 | -51.3% | 106,168 | -62.2% | 0.00% | -33.3% |
| Q2 2021 | $12,374,000 | -22.9% | 281,164 | -13.6% | 0.00% | -25.0% |
| Q1 2021 | $16,057,000 | -32.3% | 325,556 | -42.2% | 0.00% | -42.9% |
| Q4 2020 | $23,711,000 | -3.2% | 563,211 | +5.2% | 0.01% | -12.5% |
| Q3 2020 | $24,503,000 | +321.1% | 535,215 | +361.8% | 0.01% | +300.0% |
| Q2 2020 | $5,819,000 | -52.1% | 115,903 | -51.0% | 0.00% | -60.0% |
| Q1 2020 | $12,155,000 | -49.2% | 236,344 | -39.0% | 0.01% | -28.6% |
| Q4 2019 | $23,936,000 | +20.7% | 387,439 | +17.4% | 0.01% | +40.0% |
| Q3 2019 | $19,823,000 | -24.4% | 329,940 | +6.2% | 0.01% | -28.6% |
| Q2 2019 | $26,218,000 | -33.6% | 310,717 | -24.8% | 0.01% | -46.2% |
| Q1 2019 | $39,481,000 | +21.5% | 413,327 | -9.9% | 0.01% | +8.3% |
| Q4 2018 | $32,508,000 | -46.2% | 458,956 | -35.1% | 0.01% | -36.8% |
| Q3 2018 | $60,431,000 | +2.5% | 707,113 | +39.0% | 0.02% | -5.0% |
| Q2 2018 | $58,941,000 | +53.9% | 508,541 | +7.5% | 0.02% | +42.9% |
| Q1 2018 | $38,289,000 | +19.4% | 473,228 | -13.4% | 0.01% | +16.7% |
| Q4 2017 | $32,081,000 | -2.6% | 546,699 | -22.3% | 0.01% | 0.0% |
| Q3 2017 | $32,922,000 | +1027.5% | 703,460 | +767.0% | 0.01% | +1100.0% |
| Q2 2017 | $2,920,000 | +21.8% | 81,137 | +4.3% | 0.00% | 0.0% |
| Q1 2017 | $2,397,000 | +21.8% | 77,799 | +32.4% | 0.00% | 0.0% |
| Q4 2016 | $1,968,000 | +46.6% | 58,766 | +16.5% | 0.00% | – |
| Q3 2016 | $1,342,000 | -0.3% | 50,433 | -17.4% | 0.00% | – |
| Q2 2016 | $1,346,000 | -34.3% | 61,041 | -12.5% | 0.00% | -100.0% |
| Q1 2016 | $2,049,000 | -90.4% | 69,754 | -89.2% | 0.00% | -88.9% |
| Q4 2015 | $21,415,000 | -7.4% | 648,558 | +1.3% | 0.01% | -10.0% |
| Q3 2015 | $23,138,000 | -9.6% | 640,224 | +12.5% | 0.01% | 0.0% |
| Q2 2015 | $25,609,000 | +44.5% | 569,209 | -1.7% | 0.01% | +42.9% |
| Q1 2015 | $17,725,000 | +263.8% | 578,877 | +504.2% | 0.01% | +250.0% |
| Q4 2014 | $4,872,000 | +62.2% | 95,810 | +26.3% | 0.00% | +100.0% |
| Q3 2014 | $3,003,000 | -7.7% | 75,885 | +0.5% | 0.00% | 0.0% |
| Q2 2014 | $3,252,000 | +218.2% | 75,501 | +195.4% | 0.00% | – |
| Q1 2014 | $1,022,000 | – | 25,562 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 476,042 | $45,472,000 | 12.29% |
| Stonepine Capital Management, LLC | 60,840 | $5,811,000 | 3.34% |
| ACUTA CAPITAL PARTNERS, LLC | 61,000 | $5,827,000 | 2.77% |
| Virtus ETF Advisers LLC | 10,634 | $1,016,000 | 2.16% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 61,000 | $5,827,000 | 2.15% |
| ARMISTICE CAPITAL, LLC | 372,000 | $35,533,000 | 1.94% |
| Matarin Capital Management, LLC | 209,403 | $20,002,000 | 1.46% |
| Monashee Investment Management LLC | 50,000 | $4,776,000 | 1.10% |
| Granahan Investment Management | 151,322 | $14,454,000 | 0.78% |
| ALGERT GLOBAL LLC | 13,186 | $1,260,000 | 0.72% |